Portland Investment Counsel’s Perspective Therapeutics CATX Stock Holding History

Portland Investment Counsel’s Portfolio CATX Stock Details CATX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.04M	Hold	250,000	–	–	0.33%	33
2025 Q4	$688K	Hold	250,000	–	–	0.21%	42
2025 Q3	$858K	Hold	250,000	–	–	0.23%	33
2025 Q2	$940K	Buy	250,000 +60,000	+32%	+$158K	0.28%	29
2025 Q1	$405K	Buy	190,000 +40,000	+27%	+$120K	0.12%	40
2024 Q4	$479K	Buy	150,000 +79,999	+114%	+$653K	0.12%	43
2024 Q3	$935K	Hold	70,001	–	–	0.34%	27
2024 Q2	$698K	Buy	70,001 +35,746	+104%	+$517K	0.25%	34
2024 Q1	$408	Buy	34,255 +20,000	+140%	+$171K	0.12%	37
2023 Q4	$57K	Buy	+14,255	New	+$40.1K	0.02%	38
2023 Q3	–	Sell	-103,410	Closed	-$683K	–	39
2023 Q2	$683K	Buy	+103,410	New	+$628K	0.34%	30

Other funds holding CATX

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Portland Investment Counsel's CATX Position: Q1 2026 in Review

Portland Investment Counsel held its Perspective Therapeutics (CATX) position steady in Q1 2026 at 250,000 shares worth $1.04M. The position accounts for 0.33% of the portfolio, ranked #33.

Portland Investment Counsel first reported a position in CATX in Q2 2023 and has held it in 11 quarters since. 138 funds tracked by Wall St. Rank hold CATX as of Q1 2026.

Portland Investment Counsel held 250,000 shares of Perspective Therapeutics worth $1.04M as of Q1 2026.
Portland Investment Counsel left its Perspective Therapeutics share count unchanged in Q1 2026.
Perspective Therapeutics made up 0.33% of Portland Investment Counsel's portfolio in Q1 2026, its #33 holding.
Portland Investment Counsel first reported a position in Perspective Therapeutics in Q2 2023 and has held it in 11 quarters since.
138 funds tracked by Wall St. Rank held Perspective Therapeutics as of Q1 2026.

Based on Portland Investment Counsel's 13F filing for Q1 2026, filed 14 May 2026.